Sanofi (NASDAQ:SNY) Announces Quarterly Earnings Results

Sanofi (NASDAQ:SNY) posted its quarterly earnings data on Friday. The company reported $1.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $1.35, Zacks reports. The firm had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a return on equity of 20.59% and a net margin of 9.96%. The business’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.55 EPS.

Sanofi Stock Performance

Shares of SNY stock traded down $0.33 during trading hours on Monday, reaching $54.01. 93,324 shares of the company’s stock were exchanged, compared to its average volume of 2,023,751. Sanofi has a fifty-two week low of $44.05 and a fifty-two week high of $58.97. The stock has a market capitalization of $137.07 billion, a P/E ratio of 27.72, a P/E/G ratio of 1.55 and a beta of 0.60. The business has a fifty day moving average price of $56.08 and a 200-day moving average price of $51.78. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on SNY shares. Argus lifted their target price on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Citigroup raised Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Finally, StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Monday, October 14th. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Sanofi currently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.